SCHEMBL15033751

SCHEMBL15033751

Cc1nc(Nc2ccc(Cl)c(Cl)c2)c(C)c(C(=O)O)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 3/20 0.45
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
EPHX1 P07099 1/20 0.41
EPHX2 P34913 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
NPY5R Q15761 1/20 0.40
EGFR P00533 1/20 0.40
KDR P35968 1/20 0.40
RAPGEF4 Q8WZA2 1/20 0.40
DHODH Q02127 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15033718 0.85 MAPT (0.43) KMOMEN1KMT2AKDM4ELMNA
SCHEMBL15083655 0.84 CCR2 (0.51) KMOMEN1KMT2AKDM4ELMNA
SCHEMBL16257566 0.84 MEN1 (0.42) KMOMEN1KMT2AKDM4ELMNA
SCHEMBL15033697 0.83 ADORA3 (0.42) KMOMEN1KMT2AKDM4ELMNA
SCHEMBL15033668 0.81 KMO (0.58) KMOMEN1KMT2AHTTSMN1; SMN2
SCHEMBL14653353 0.76 CCR2 (0.44) LMNAMAPTEPHX2EGFRKDR
SCHEMBL15033805 0.74 SYK (0.58) MEN1KMT2ALMNAHTTEGFR
SCHEMBL12065070 0.72 KMO (0.44) KMOMEN1KMT2AKDM4ELMNA
SCHEMBL12279148 0.70 STK17A (0.53) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL16257590 0.68 KIT (0.50) KMOKDRRAPGEF4DHODHHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2721025-B1 NEW SELECTIVE CCR2 ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-11-25 EP disclosed
US-20130150354-A1 NEW SELECTIVE CCR2 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150354-A1 NEW SELECTIVE CCR2 ANTAGONISTS CCR2, CCRL2, CXCR2 KMO 1751/4885MEN1 4880/4885KMT2A 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.